

4.01.21	Noninvasive Prenatal Screening for Fetal Aneuploidies, Microdeletions, and Twin Zygosity Using Cell-Free Fetal DNA		
Original Policy Date:	March 29, 2013	Effective Date:	April 1, 2021
Section:	4.0 OB/Gyn/Reproduction	Page:	Page 1 of 33

Policy Statement

Nucleic acid sequencing-based testing (Noninvasive Prenatal Testing or NIPT, also referred to as Noninvasive Prenatal Screening or NIPS) of a pregnant individual's plasma to screen for trisomy 21, 18, and 13 as an alternative to the California Prenatal Screening Program or similar (see Policy Guidelines section), may be considered **medically necessary** in women with singleton pregnancies.

Performing both the California Prenatal Screening Program (or similar) testing and NIPT during the same pregnancy is considered **not medically necessary**.

Nucleic acid sequencing-based testing of a pregnant individual's plasma (i.e., circulating cell free DNA) is considered **investigational** in the following situations:

- I. For trisomy 21 in individuals with twin or multiple pregnancies
- II. For trisomy 13 and/or 18 other than in the situations specified above
- III. For microdeletions
- IV. For fetal sex chromosome aneuploidies
- V. For single gene disorders, either individually or as a panel (e.g., Vistara)
- VI. For Vanadis NIPT to screen for trisomy 21, 18 and 13
- VII. For twin zygosity
- VIII. For other aneuploidies or genetic disorders not considered medically necessary as noted above, including but not limited to comprehensive screening of all 22 autosomes

NOTE: Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Karyotyping would be necessary to exclude the possibility of a false-positive, nucleic acid sequencing-based test. Before testing, women should be counseled about the risk of a false-positive test.

In Committee Opinion No. 640, the American College of Obstetricians and Gynecologists (ACOG) (2015) recommended that all patients receive information on the risks and benefits of various methods of prenatal screening and diagnostic testing for fetal aneuploidies, including the option of no testing.

Studies published to date on noninvasive prenatal screening for fetal aneuploidies have reported rare but occasional false-positives. False-positive findings have been found to be associated with factors including placental mosaicism, vanishing twins, and maternal malignancies. Diagnostic testing is necessary to confirm positive cell-free fetal DNA tests, and management decisions should not be based solely on the results of cell-free fetal DNA testing. The ACOG further recommended that patients with indeterminate or uninterpretable (i.e., "no call") cell-free fetal DNA test results be referred for genetic counseling and offered ultrasound evaluation and diagnostic testing because "no-call" findings have been associated with an increased risk of aneuploidy.

Any of the 22 pairs of chromosomes that regulate the somatic characters of the body are known as autosomes, whereas the single pair (23rd) of chromosomes that determines the sex of an organism (including sex-linked traits) are known as sex chromosomes or allosomes.

Microdeletions are genomic disorders that occur when DNA is lost during the replication process. Common microdeletion syndromes include: DiGeorge syndrome, Angelman Syndrome, Cri-du-chat Syndrome, Prader-Willi Syndrome, Jacobsen Syndrome, Langer-Giedion Syndrome, and Wolf-Hirschhorn Syndrome.

Cell-free fetal DNA screening does not assess the risk of neural tube defects. Patients choosing NIPT (CPT code 81420) should continue to be offered ultrasound (usually between 11 and 14 weeks gestation; CPT code 76813) or maternal serum α -fetoprotein (AFP; CPT code 82105) screening. CPT codes 81420, 76813 and 82105 are only allowable for patients choosing the NIPT option during the course of the pregnancy.

California Prenatal Screening Program

The California Prenatal Screening Program (using serum analyte testing and ultrasound) must be offered to all pregnant women who reside in California. NIPT is considered an equivalent test and is offered to Blue Shield of California patients as an alternative. However, both should not be done during the same pregnancy. When multiple screening tests are performed, unless they are designed to function together (i.e., the quad test, where each of the 4 blood tests has been studied and found to be independent of the others), there is a risk of increasing the number of false-positive results with an uncertain improvement in the actual detection rate for the abnormality. An increase in false positives results in an increase in invasive diagnostic testing (i.e., Chorionic Villus Sampling or amniocentesis) that has significant independent risks from doing those procedures.¹⁷

Patients choosing the California Prenatal Screening program would not be allowed CPT code 81420 for NIPT testing during the same pregnancy (see Coding in the Policy Guidelines section for CPT codes).

Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Coding

The Vistara test (by Natera) is a panel of 25 individual single gene disorders. It is billed using a combination of 81302 for MECP2 (Rett syndrome) and 81442 for Noonan spectrum disorders (minimum 12 gene panel).

The following CPT code represents Vanadis® Non-Invasive Prenatal Testing (NIPT), a non-invasive prenatal assay to screen for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome):

- **0168U:** Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy

If the test is run as a genomic sequence analysis panel that includes analysis of all 3 chromosomes and does not involve an algorithmic analysis, the following code is available:

- **81420:** Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21

There is a specific MAAA CPT code for the Ariosa Diagnostics Harmony™ Prenatal Test:

- **81507:** Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

If the codes above do not apply and the test involves MAAA, it would be reported with the unlisted MAAA code (81599). If the codes above do not apply, the unlisted molecular pathology code 81479 is available when the test does not involve an algorithmic analysis.

There is a specific code for testing maternal blood for fetal chromosomal microdeletion(s):

- **81422:** Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood

The California Prenatal Screening Program may use the following options and codes for screening tests:

Quad Marker Screening*

- One blood specimen drawn at 15 to 20 weeks of pregnancy
 - **82105:** Alpha-fetoprotein (AFP); serum
 - **82677:** Estriol
 - **84702:** Gonadotropin, chorionic (hCG); quantitative
 - **86336:** Inhibin A

*Note: also known as Expanded Alpha Fetal Protein (XAFP)

Serum (Blood) Integrated Screening

- First blood specimen drawn at 10 weeks to 13 weeks and 6 days of pregnancy
- Second blood specimen drawn at 15 to 20 weeks of pregnancy
 - **82677:** Estriol
 - **82105:** Alpha-fetoprotein (AFP); serum

and

 - **84163:** Pregnancy-associated plasma protein-A (PAPP-A)
 - **84702:** Gonadotropin, chorionic (hCG); quantitative
 - **86336:** Inhibin A

Full Integrated Screening

- First blood specimen is drawn at 10 weeks to 13 weeks and 6 days of pregnancy
- Nuchal Translucency (NT) ultrasound is performed at a perinatal diagnostic center (PDC) at 11 weeks and 2 days to 14 weeks and 2 days of pregnancy
- Second blood specimen is drawn at 15 to 20 weeks of pregnancy
 - **76813:** Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; single or first gestation
 - **82677:** Estriol
 - **82105:** Alpha-fetoprotein (AFP); serum

and

 - **84163:** Pregnancy-associated plasma protein-A (PAPP-A)
 - **84702:** Gonadotropin, chorionic (hCG); quantitative
 - **86336:** Inhibin A

Description

National guidelines recommend that all pregnant women be offered screening for fetal chromosomal abnormalities, most of which are aneuploidies, an abnormal number of chromosomes. Trisomy syndromes are aneuploidies involving 3 copies of 1 chromosome. Trisomies 21, 18, and 13 are the most common forms of fetal aneuploidy that survive to birth. There are numerous limitations to standard screening for these disorders using the maternal serum and fetal ultrasound. Noninvasive prenatal screening analyzing cell-free fetal DNA in maternal serum is a potential complement or alternative to conventional serum screening.

Noninvasive prenatal screening using cell-free fetal DNA has also been proposed to screen for microdeletions. Prenatal testing for twin zygosity using cell-free fetal DNA has been proposed to inform decisions about early surveillance for twin-to-twin transfusion syndrome and other monochorionic twin-related abnormalities.

Related Policies

- Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
- Invasive Prenatal (Fetal) Diagnostic Testing

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Act. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Act for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of noninvasive prenatal screening tests using cell-free fetal DNA.

Commercially available tests include but are not limited to the following:

- Myriad Prequel(TM) Prenatal Screen (Myriad Women's Health, Counsyl) utilizes whole genome sequencing for detecting aneuploidy including T21, T18, T13
- VisibiliT (Sequenom Laboratories, now LabCorp) tests for T21 and T18, and tests for sex.
- MaterniT21 PLUS (Sequenom Laboratories, now LabCorp) core test includes T21, T18, T13, and fetal sex aneuploidies. The enhanced sequencing series includes testing for T16, T22, and 7 microdeletions: 22q deletion syndrome (DiGeorge syndrome), 5p (cri du chat syndrome), 15q (Prader-Willi and Angelman syndromes), 1p36 deletion syndrome, 4p (Wolf-Hirschhorn syndrome), 8q (Langer-Giedion syndrome), and 11q (Jacobsen syndrome). The test uses MPS and reports results as positive or negative. The enhanced sequencing series is offered on an opt-out basis.
- Harmony (Ariosa Diagnostics, now Roche) tests for T21, T18, and T13. The test uses directed DNA analysis and results are reported as a risk score.
- Panorama (Natera) is a prenatal test for detecting T21, T18, and T13, as well as select sex chromosome abnormalities. It uses single nucleotide variant technology; results are reported as a risk score. An extended panel tests for 5 microdeletions: 22q deletion syndrome (DiGeorge syndrome), 5p (cri du chat syndrome), 15q11-13 (Prader-Willi and Angelman syndromes), and 1p36 deletion syndrome. Screening for 22q11.2 will be included in the panel unless the opt-out option is selected; screening for the remaining 4 microdeletions is offered on an opt-in basis.

- Verifi® (Verinata Health, now Illumina) is a prenatal test for T21, T18, and T13. The test uses MPS and calculates a normalized chromosomal value, reporting results as 1 of 3 categories: no aneuploidy detected, aneuploidy detected, or aneuploidy suspected.
- InformaSeq (Integrated Genetics, now LabCorp) is a prenatal test for detecting T21, T18, and T13, with optional testing for select sex chromosome abnormalities. It uses the Illumina platform and reports results in a similar manner.
- QNatal Advanced (Quest Diagnostics) tests for T21, T18, and T13.
- Vanadis NIPT Solution (PerkinElmer) tests for T21, T18, and T13.
- Veracity (NIPD Genetics) tests for T21, T18, and T13, sex chromosome aneuploidies, and microdeletions.

Rationale

Background

Fetal Aneuploidy

Fetal chromosomal abnormalities occur in approximately 1 in 160 live births. Most fetal chromosomal abnormalities are aneuploidies, defined as an abnormal number of chromosomes. The trisomy syndromes are aneuploidies involving 3 copies of 1 chromosome. The most important risk factor for trisomy syndromes is maternal age. The approximate risk of a trisomy 21 (T21; Down syndrome)-affected birth is 1 in 1100 at age 25 to 29. The risk of a fetus with T21 (at 16 weeks of gestation) is about 1 in 250 at age 35 and 1 in 75 at age 40.¹

T21 is the most common chromosomal aneuploidy and provides the impetus for current maternal serum screening programs. Other trisomy syndromes include T18 (Edwards syndrome) and T13 (Patau syndrome), which are the next most common forms of fetal aneuploidy, although the percentage of cases surviving to birth is low and survival beyond birth is limited. Detection of T18 and T13 early in pregnancy can facilitate preparation for fetal loss or early intervention.

Fetal Aneuploidy Screening

Standard aneuploidy screening involves combinations of maternal serum markers and fetal ultrasound done at various stages of pregnancy. The detection rate for various combinations of noninvasive testing ranges from 60% to 96% when the false-positive rate is set at 5%. When tests indicate a high-risk of a trisomy syndrome, direct karyotyping of fetal tissue obtained by amniocentesis or chorionic villous sampling (CVS) is required to confirm that T21 or another trisomy is present. Both amniocentesis and CVS are invasive procedures and have procedure-associated risks of fetal injury, fetal loss, and infection. A new screening strategy that reduces unnecessary amniocentesis and CVS procedures or increases detection of T21, T18, and T13 could improve outcomes. Confirmation of positive noninvasive screening tests with amniocentesis or CVS is recommended; with more accurate tests, fewer women would receive positive screening results.

Commercial, noninvasive, sequencing-based testing of maternal serum for fetal trisomy syndromes is now available. The testing technology involves the detection of cell-free fetal DNA fragments present in the plasma of pregnant women. As early as 8 to 10 weeks of gestation, these fetal DNA fragments comprise 6% to 10% or more of the total cell-free fetal DNA in a maternal plasma sample. The tests are unable to provide a result if the fetal fraction is too low (i.e., <4%). The fetal fraction can be affected by maternal and fetal characteristics. For example, the fetal fraction was found to be lower at higher maternal weights and higher with increasing fetal crown-rump length.

Twin Zygosity Testing

Twin gestations occur in approximately 1 in 30 live births in the United States and have a 4- to 10-fold increased risk of perinatal complications.² Dizygotic or "fraternal" twins occur from ovulation and fertilization of 2 oocytes, which results in dichorionic (DC) placentation and 2 separate placentas. In contrast to DC twins, MC twin pregnancies share their blood supply.

Monochorionic (MC) twins account for about 20% of twin gestations and are at higher risk of structural defects, miscarriage, preterm delivery, and selective fetal growth restriction compared to DC twins.² Up to 15% of MC twin pregnancies are affected by twin to twin transfusion syndrome (TTTS), a condition characterized by relative hypovolemia of 1 twin and hypervolemia of the other.³ According to estimates from live births, TTTS occurs in up to 15% of MC twin pregnancies. In these twin pregnancies, serial fetal ultrasound examinations are necessary to monitor for development of TTTS as well as selective intrauterine growth restriction because these disorders have high morbidity and mortality, and are amenable to interventions that can improve outcomes.³ Noninvasive prenatal testing (NIPT) using cell-free fetal DNA to determine zygosity in twin pregnancies could potentially inform decisions about early surveillance for TTTS and other MC twin-related abnormalities. In particular, determining zygosity with NIPT could potentially assist in the assessment of chorionicity when ultrasound findings are not clear.³

Cell-Free Fetal DNA Analysis Methods

Sequencing-based tests use 1 of 2 general approaches to analyzing cell-free fetal DNA. The first category of tests uses quantitative or counting methods. The most widely used technique to date uses massively parallel sequencing (MPS; also known as next-generation sequencing). DNA fragments are amplified by polymerase chain reaction; during the sequencing process, the amplified fragments are spatially segregated and sequenced simultaneously in a massively parallel fashion. Sequenced fragments can be mapped to the reference human genome to obtain numbers of fragment counts per chromosome. The sequencing-derived percent of fragments from the chromosome of interest reflects the chromosomal representation of the maternal and fetal DNA fragments in the original maternal plasma sample. Another technique is direct DNA analysis, which analyzes specific cell-free fetal DNA fragments across samples and requires approximately a tenth the number of cell-free DNA fragments as MPS. The digital analysis of selected regions (DANSR™) is an assay that uses direct DNA analysis.

The second general approach is single nucleotide variant-based methods. They use targeted amplification and analysis of approximately 20000 single nucleotide variants on selected chromosomes (e.g., 21, 18, 13) in a single reaction. A statistical algorithm is used to determine the number of each type of chromosome. At least some of the commercially available cell-free fetal DNA prenatal tests also test for other abnormalities including sex chromosome abnormalities and selected microdeletions.

A newer approach to cell free DNA testing called the Vanadis NIPT does not involve amplification or sequencing. The assay uses maternal serum and applies a series of enzymes to create labelled rolling circle replication products (RCPs) from chromosomal cell-free DNA targets, which are then converted to fluorescent DNA molecules and labeled with chromosome-specific fluorophores. The labeled fluorescent DNA molecules are deposited to a microfilter plate and counted with an automated imaging device. The ratio between the number of each chromosome-specific fluorescent DNA molecules is transferred for risk calculation to proprietary software to calculate the likelihood of a trisomy. Currently, Vanadis NIPT provides results for trisomy 21, trisomy 18 and trisomy 13; although, additional aneuploidies and microdeletions might be added in the future.

Copy Number Variants and Clinical Disorders

Microdeletions (also known as submicroscopic deletions) are chromosomal deletions that are too small to be detected by microscopy or conventional cytogenetic methods. They can be as small as 1 and 3 megabases long. Along with microduplications, microdeletions are collectively known as copy number variants. Copy number variants can lead to disease when the change in copy number of a dose-sensitive gene or genes disrupts the ability of the gene(s) to function and affects the amount of protein produced. A number of genomic disorders associated with microdeletion have been identified, which may be associated with serious clinical features, such as cardiac anomalies, immune deficiency, palatal defects, and developmental delay as in DiGeorge syndrome. Some of the syndromes (e.g., DiGeorge) have complete penetrance yet marked variability in clinical expressivity. A contributing factor is that the breakpoints of the

microdeletions may vary, and there may be a correlation between the number of haploinsufficient genes and phenotypic severity.

A proportion of microdeletions are inherited and some are de novo. Accurate estimates of the prevalence of microdeletion syndromes during pregnancy or at birth are not available. The risk of a fetus with a microdeletion syndrome is independent of maternal age. There are few population-based data and most studies published to date have based estimates on phenotypic presentation. The 22q11.2 (DiGeorge) microdeletion is the most common associated with a clinical syndrome. Table 1 provides prevalence estimates for the most common microdeletion syndromes. These numbers likely underestimate the prevalence of these syndromes in the prenatal population because the population of variant carriers includes phenotypically normal or very mildly affected individuals.

Table 1. Recurrent Microdeletion Syndromes

Syndrome	Location	Estimated Prevalence
DiGeorge	22q11.2	1/2000
1p36 deletion	1p36-	1/5000
Prader-Willi and Angelman	Del 15q11.2	1/20,000
Wolf-Hirschhorn	4p-	1/50,000 to 1/20,000
Cri du chat	5p-	1/50,000
Miller-Dieker	Del 17p13.3	1 /100,000

Adapted from Chitty et al (2018).⁴

Routine prenatal screening for microdeletion syndromes is not recommended by national organizations. Current practice is to offer invasive prenatal diagnostic testing in select cases to women when a prenatal ultrasound indicates anomalies (e.g., heart defects, cleft palate) that could be associated with a particular microdeletion syndrome. Samples are analyzed using fluorescence in situ hybridization, chromosomal microarray analysis, or karyotyping. Additionally, families at risk (e.g., those known to have the deletion or with a previously affected child) generally receive genetic counseling and those who conceive naturally may choose prenatal diagnostic testing. Most affected individuals, though, are identified postnatally based on clinical presentation and may be confirmed by genetic testing. Using 22q11.2 deletion syndrome as an example, although clinical characteristics vary, palatal abnormalities (e.g., cleft palate) occur in approximately 69% of individuals, congenital heart disease in 74%, and characteristic facial features are present in a majority of individuals of northern European heritage.

Literature Review

The review was informed by 2 Blue Cross Blue Shield Association Technology Evaluation Center (TEC) Assessments. One TEC Assessment (2013) focused on detection of trisomy 21 (T21),⁵ and the other TEC Assessment (2014) addressed detection of fetal aneuploidies other than T21 (specifically trisomies 13 [T13] and 18 [T18], and fetal sex chromosome aneuploidies).⁶

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Noninvasive Prenatal Screening for Chromosomal Trisomies in Singleton Pregnancies Clinical Context and Test Purpose

The purpose of NIPS using cell-free fetal DNA is to screen for fetal chromosomal abnormalities (e.g., trisomies 21, 18, 13 [T21, T18, T13]). It can be used as a complement or alternative to

conventional serum screening. National guidelines have recommended that all pregnant women be offered screening for aneuploidies. Positive cell-free fetal DNA tests need to be confirmed using invasive testing and, if more accurate than standard screening may reduce the need for invasive testing and associated morbidities.

The purpose of NIPS using analysis of cell-free fetal DNA in patients who have singleton pregnancy is to inform a decision whether to proceed with diagnostic testing.

The question addressed in this evidence review is as follows: In pregnant individuals, does NIPS for chromosomal aneuploidies lead to improvements in health outcomes?

The following PICO was used to select literature to inform this review.

Patients

The relevant population of interest are women with first- and second-trimester singleton pregnancy.

Interventions

The intervention of interest is NIPS using analysis of cell-free fetal DNA for detection of chromosomal trisomies.

Comparators

The following tests are currently being used to make decisions about identifying fetal chromosomal abnormalities: conventional serum and ultrasound screening followed by invasive diagnostic testing as well as standard of care without screening.

Outcomes

The primary outcomes of interest are test accuracy and validity, reductions in miscarriages associated with invasive confirmatory testing, and reduction in the use of other noninvasive and invasive tests received by the pregnant individuals. The timing for testing is generally in the first trimester of pregnancy and can be early in the second trimester.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

A Cochrane review by Badeau et al (2017) included 65 studies on the screening of women with a singleton pregnancy (see Table 2).² None of the studies was rated at low-risk of bias, although they were considered to have a low bias in the domains of the index test and reference standard. Results were assessed separately for massively parallel sequencing (MPS) and targeted MPS (TMPS), for unselected pregnant women and high-risk women, and for T21, T18, and T13 (see Tables 3 and 4). For both unselected and high-risk pregnant women, sensitivity for T21 was 99.2% or higher and specificity was 99.9% or higher.

Adding screening for T18 and T13 resulted in an overall sensitivity of 94.9% in unselected pregnant women and 98.8% in high-risk women. Specificity was 99.9% for both groups. Reviewers calculated that out of 100000 high-risk pregnancies, 5851 would be affected by T21, T18, or T13. Of these 5781 (MPS) and 5787 (TMPS) would be detected and 70 (MPS) and 64 (TMPS) cases would be missed (see Table 4). Of the 94149 unaffected women, 94 would undergo an

unnecessary invasive test. Reviewers concluded that the performance of the nucleic acid sequencing-based test was sensitive and highly specific to detect fetal trisomies T21, T18, and T13 in high-risk women but was not sufficient to replace current invasive diagnostic tests. Available data were considered insufficient to evaluate diagnostic performance in an unselected population.

Table 2. Characteristics of Systematic Reviews

Study	No. of Studies	Study Populations	Designs of Studies	Reference Standard of Studies	No. of Studies Rated as "High" or "Unclear" Risk of Bias		
					No Domains	1-2 Domains	>2 Domains
Badeau et al (2017) ^L	65	Women with singleton pregnancy	RCTs, cohort studies, case-control	Fetal karyotyping or neonatal clinical examination	0	41	24

RCT: randomized controlled trial.

Table 3. Systematic Reviews Results for Unselected Pregnant Women

Test	Affected Pregnancies (Unaffected Pregnancies)	Sensitivity (95% CI), %	Specificity (95% CI), %	FN per 100,000 Cases	FP per 100,000 Cases	Disease Prevalence (95% CI)
T21 MPS	8 (1733)	100 (67.6 to 100)	100 (99.8 to 100)	0	0	0.46 (0.24 to 5.21)
T21 TMPS	88 (20,679)	99.2 (78.2 to 100)	100 (>99.9 to 100)	4	0	
T18 MPS	2 (1739)	100 (34.3 to 100)	99.9 (99.7 to 100)	0	100	0.11 (0.06 to 0.36)
T18 TMPS	22 (20,553)	90.9 (70.0 to 97.7)	100 (99.9 to 100)	10	0	
T13 MPS	1 (1740)	100 (20.7 to 100)	100 (99.8 to 100)	0	0	0.12 (0.01 to 0.52)
T13 TMPS	8 (14,154)	65.1 (9.16 to 97.2)	100 (99.9 to 100)	41	0	
T21, T18, T13 MPS	11 (1730)	100 (74.1 to 100)	99.9 (99.8 to 99.9)	0	99	0.63 (0.32 to 5.73)
T21, T18, T13 TMPS	118 (20,649)	94.9 (89.1 to 97.7)	99.9 (99.8 to 99.9)	32	99	

CI: confidence interval; FN: false-negative (missed cases); FP: false-positive; MPS: massively parallel sequencing; TMPS: targeted massively parallel sequencing; T13: trisomy 13; T18: trisomy 18; T21: trisomy 21.

Table 4. Systematic Reviews Results for High-Risk Pregnant Women

Test	Affected Pregnancies (Unaffected Pregnancies)	Sensitivity (95% CI), %	Specificity (95% CI), %	FN per 100,000 Cases	FP per 100,000 Cases	Disease Prevalence (95% CI)
T21 MPS	1048 (15,937)	99.7 (98 to 100)	99.9 (99.8 to 100)	15	95	4.95 (0.44 to 27.66)
T21 TMPS	246 (4380)	99.2 (96.8 to 99.8)	100 (99.8 to 100)	40	0	
T18 MPS	332 (16,180)	97.8 (92.5 to 99.4)	99.9 (99.8 to 100)	32	99	1.46 (0.22 to 17.02)
T18 TMPS	112 (4010)	98.2 (93.1 to 99.6)	100 (99.8 to 100)	26	0	
T13 MPS	128 (13,810)	95.6 (86.1 to 98.9)	99.8 (99.8 to 99.9)	46	198	1.09 (0.04 to 3.54)
T13 TMPS	20 (293)	100 (83.9 to 100)	100 (98.7 to 100)	0	0	
T21, T18, T13 MPS	1508 (15,797)	98.8 (97.2 to 99.5)	99.9 (99.7 to 100)	70	94	5.85 (0.67 to 46.81)
T21, T18, T13 TMPS	378 (4282)	98.9 (97.2 to 99.6)	99.9 (99.8 to 100)	64	94	

CI: confidence interval; FN: false-negative (missed cases); FP: false-positive; MPS: massively parallel sequencing; TMPS: targeted massively parallel sequencing; T13: trisomy 13; T18: trisomy 18; T21: trisomy 21.

Section Summary: Clinical Validity

A meta-analysis of data available from published studies reported sensitivities of 98.8% to 98.9% and specificities of 99.9% for NIPS for detecting T21, T18, and T13 in high-risk women with singleton pregnancies. Calculation indicated that 64 to 70 affected cases would be missed out of 100000 pregnancies. The available studies providing data separately for an unselected population found sensitivities ranging from 94.9% (MPS) to 100% (TMPS), and specificities of 99.9% for detection of T21, T18, and T13. The specificity of 99.9% is similar to that seen in high-risk women, with an estimated 0 (MPS) to 32 (TMPS) affected cases missed out of 100000 pregnancies.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Review of Evidence

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

No studies identified provided direct evidence of the clinical utility that NIPS using analysis of cell-free fetal DNA changed the management of patients having singleton pregnancies.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Two TEC Assessments (2013, 2014) constructed decision models to predict health outcomes of sequencing-based testing compared with standard testing.⁵ The model in the 2013 TEC Assessment focused on T21. In this model, the primary health outcomes of interest included the number of cases of aneuploidy correctly identified, number of cases missed, the number of invasive procedures potentially avoided (i.e., with a more sensitive test), and the number of miscarriages potentially avoided as a result of fewer invasive procedures. The results were calculated for a high-risk population of women ages 35 years or older (estimated antenatal prevalence of T21, 0.95%) and for an average-risk population including women of all ages electing an initial screen (estimated antenatal prevalence of T21, 0.25%). For women testing positive on the initial screen and offered an invasive, confirmatory procedure, it was assumed that 60% would accept amniocentesis or chorionic villous sampling. Sensitivities and specificities for both standard and sequencing-based screening tests were varied to represent the range of possible values; estimates were taken from published studies whenever possible.

According to the model results, sequencing-based testing improved outcomes for both high-risk and average-risk women. As an example, assuming there were 4.25 million births in the U. S. per year and 2/3 of the population of average-risk pregnant women (2.8 million) accepted screening, the following outcomes would occur for the 3 screening strategies under consideration:

- Standard screening: Of the 2.8 million screened with the stepwise sequential screen, 87780 would have an invasive procedure (assuming 60% uptake after a positive screening test and a recommendation for confirmation), 448 would have a miscarriage, and 3976 (94.7%) of 4200 Down syndrome (T21) cases would be detected.
- Sequencing as an alternative to standard screening: If sequencing-based testing were used instead of standard screening, the number of invasive procedures would be reduced to 7504 and the number of miscarriages reduced to 28, while the cases of Down syndrome detected would increase to 4144 (97.6% of total) of 4200, using conservative estimates.
- Sequencing following standard screening: Another testing strategy would be to add sequencing-based testing only after a positive standard screen. In this scenario, invasive procedures would be further decreased to 4116, miscarriages would remain at 28, but fewer Down syndrome cases would be detected (3948/4200 [94.0% of total]). Thus, while this strategy has the lowest rate of miscarriages and invasive procedures, it detects fewer cases than sequencing-based testing alone.

The model in the 2014 TEC Assessment included T13 and T18 (but not sex chromosome aneuploidies, due to the difficulty of defining relevant health outcomes). The model was similar

but not identical to that previously used to evaluate T21. As in earlier model, outcomes of interest included the number of cases of aneuploidy correctly detected and the number of cases missed, and findings were calculated separately for a high-risk population of women ages 35 or older and a low-risk population. The model assumed that 75% of high-risk and 50% of low-risk women who tested positive on the initial screen would proceed to an invasive test. (The T21 model assumed a 60% uptake rate of invasive confirmatory testing.) A distinctive feature of the 2014 modeling study was that it assumed screening for T21 was done concurrently with screening for T13 and T18 and that women who choose invasive testing would do so because of a desire to detect T21. Consequently, miscarriages associated with invasive testing were not considered an adverse event of T13 or T18 screening.

The model compared 2 approaches with screening: (1) a positive sequencing-based screen followed by diagnostic invasive testing; and (2) a positive standard noninvasive screen followed by diagnostic invasive testing. As in the T21 modeling study, sensitivities and specificities for both standard and sequencing-based screening tests were varied to represent the range of possible values; estimates were taken from published studies whenever possible. Assuming that a hypothetical population of 100000 pregnant women was screened, the model had the following findings.

- High-risk women: Assuming 75% uptake after a positive screen, the maximum cases detectable in the hypothetical population of 100000 pregnancies would be 127 T18 cases and 45 T13 cases. Standard noninvasive screening would identify 123 of the 127 T18 cases, and sequencing-based screening would identify 121 of 127 cases. Additionally, standard noninvasive screening would identify 37 of 45 T13 cases, and sequencing-based screening would identify 39 of 45 T13 cases.
- Low-risk women: Assuming 50% uptake after a positive screen, the maximum cases detectable in the hypothetical population of 100000 pregnancies would be 20 T18 cases and 6 T13 cases. Each initial screening test would identify 19 of the 20 T18 cases and 5 of the 6 T13 cases.

Results of the modeling suggest that sequencing-based tests detect a similar number of T13 and T18 cases and miss fewer cases than standard noninvasive screening. Even in a hypothetical population of 100000 women, however, the potential number of detectable cases is low, especially for T13 and for low-risk women.

In addition to the TEC Assessments, several other decision models have been published. For example, Ohno and Caughey (2013) published a decision model comparing the use of sequencing-based tests in high-risk women with confirmatory testing (i.e., as a screening test) and without confirmatory testing (i.e., as a diagnostic test).⁸ Results of the model concluded that using sequencing-based tests with confirmatory test results in fewer losses of normal pregnancies compared with sequencing-based tests used without a confirmatory test. The model assumed estimates using the total population of 520000 high-risk women presenting for first-trimester care each year in the U. S. Sequencing-based tests used with confirmatory testing resulted in 1441 elective terminations (all with Down syndrome). Without confirmatory testing, sequencing-based tests resulted in 3873 elective terminations, 1449 with Down syndrome and 2424 without Down syndrome. There were 29 procedure-related pregnancies losses when confirmatory tests were used. The decision model did not address T18 or T13.

Section Summary: Clinically Useful

Modeling studies using published estimates of diagnostic accuracy and other parameters predict that sequencing-based testing as an alternative to standard screening would increase the number of T21 (i.e., Down syndrome) cases detected and when included in the model, a large decrease in the number of invasive tests and associated miscarriages.

Noninvasive Prenatal Screening for Sex Chromosome Aneuploidies in Singleton Pregnancies Clinical Context and Test Purpose

The purpose of NIPS using analysis of cell-free fetal DNA in women who have singleton pregnancy is to inform a decision whether to proceed with diagnostic testing.

The question addressed in this evidence review are as follows: In pregnant individuals, does NIPS for sex chromosome aneuploidies lead to improvements in health outcomes?

The following PICO was used to select literature to inform this review.

Patients

The relevant population of interest are women with first- and second-trimester singleton pregnancy.

Interventions

The intervention of interest is NIPS using analysis of cell-free fetal DNA.

Comparators

The following tests are currently being used to make decisions about identifying fetal chromosomal abnormalities: conventional serum and ultrasound screening followed by invasive diagnostic testing as well as standard of care without screening.

Outcomes

The primary outcomes of interest are test accuracy and validity, reductions in miscarriages associated with invasive confirmatory testing, and reduction in the use of other noninvasive and invasive tests received by the pregnant individuals. The timing for testing is generally in the first trimester of pregnancy and can be early in the second trimester.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

The Cochrane review by Bateau et al (2017) evaluated the diagnostic accuracy of NIPS for sex chromosome anomalies.² Twelve studies were identified on the 45, X chromosome with sensitivities of 91.7% to 92.4% and specificities of 99.6% to 99.8% (see Table 5). Reviewers calculated that of 100000 pregnancies, 1039 would be affected by 45, X chromosome. Of these, 953 (MPS) and 960 (TMPS) would be detected and 86 and 79 cases, respectively, would be missed. Of the 98961 unaffected women, 396 and 198 pregnant women would undergo an unnecessary invasive test.

Bateau et al (2017) were unable to perform meta-analyses of NIPS for chromosomes 47, XXX, 47, XXY, and 47, XYY due to insufficient evidence.

Table 5. Systematic Review Testing Results for Sex Chromosome Aneuploidies in High-Risk Pregnant Women

Test	Affected Pregnancies (Unaffected Pregnancies)	Sensitivity (95% CI), %	Specificity (95% CI), %	FN per 100,000 Cases	FP per 100,000 Cases	Disease Prevalence (95% CI)
45, X MPS	119 (7440)	91.7 (78.3 to 97.1)	99.6 (98.9 to 99.8)	86	396	1.04 (0.27 to 18.58)

Test	Affected Pregnancies (Unaffected Pregnancies)	Sensitivity (95% CI), %	Specificity (95% CI), %	FN per 100,000 Cases	FP per 100,000 Cases	Disease Prevalence (95% CI)
45, X TMPS	79 (985)	92.4 (84.1 to 96.5)	99.8 (98.3 to 100)	79	198	
Sex chromosomes MPS ^a	151 (7452)	91.9 (73.8 to 97.9)	99.5 (98.8 to 99.8)	124	492	1.53 (0.45 to 18.58)
Sex chromosomes TMPS ^a	96 (968)	93.8 (86.8 to 97.2)	99.6 (98.1 to 99.9)	95	394	

CI: confidence interval; FN: false-negative; FP: false-positive; MPS: massively parallel sequencing; TMPS: targeted massively parallel sequencing.

^a Chromosomes 45, X, 47, XXX, 47, XXY and 47, XYY combined.

Section Summary: Clinically Valid

There is less data on the diagnostic performance of sequencing-based tests for detecting sex chromosome aneuploidies. The available data have suggested that diagnostic performance for detecting these other fetal aneuploidies is not as high as it is for detection of T21, T18, and T13 and there is a higher rate of false-positive tests.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Review of Evidence

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No studies identified provided direct evidence of the clinical utility that NIPS using analysis of cell-free fetal DNA changed the management of patients having singleton pregnancies.

Sex chromosome aneuploidies (e.g., 45, X [Turner syndrome]; 47, XXY, 47, XYY) occur in approximately 1 in 400 live births. These aneuploidies are typically diagnosed postnatally, sometimes not until adulthood, such as during evaluation of diminished fertility. Alternatively, sex chromosome aneuploidies may be diagnosed incidentally during invasive karyotype testing of pregnant women at high-risk for Down syndrome. It not possible to construct a chain of evidence for clinical utility due to the lack of sufficient evidence on clinical validity and diagnostic challenges noted.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Section Summary: Clinically Useful

The clinical utility of prenatal diagnosis of sex chromosome aneuploidies is uncertain. Potential benefits of early identification (e.g., the opportunity for early management of the manifestations of the condition) must be balanced against potential harms that can include stigmatization and distortion of a family's view of the child.

Noninvasive Prenatal Screening for Fetal Aneuploidies in Twin and Multiple Pregnancies

Clinical Context and Test Purpose

The purpose of NIPS using analysis of cell-free fetal DNA in patients who have a twin or other multiple pregnancy is to inform a decision whether to proceed with diagnostic testing.

The questions addressed in this evidence review are as follows: In patients who have a twin or multiple pregnancy, does NIPS for aneuploidies lead to improvements in health outcomes?

The following PICO was used to select literature to inform this review.

Patients

The relevant population of interest is women with first- and second-trimester twin or other multiple pregnancy.

Interventions

The intervention of interest is NIPS using analysis of cell-free fetal DNA.

The test would be used in the primary care or specialty care setting (i.e., obstetrics-gynecology). Genetic counseling may also be necessary. The timing for testing is generally in the first trimester of pregnancy and can be early in the second trimester.

Comparators

The following tests are currently being used to make decisions about identifying sex chromosome aneuploidies: conventional serum and ultrasound screening followed by invasive diagnostic testing as well as standard of care without screening.

Outcomes

The primary outcomes of interest are test accuracy and validity, reductions in miscarriages associated with invasive confirmatory testing, and reduction in the use of other noninvasive and invasive tests received by the pregnant individuals.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence Systematic Reviews

A meta-analysis by Liao et al (2017) identified 10 studies published through July 2016 that reported on the diagnostic performance of NIPS for identifying aneuploidies in twin pregnancies (see Table 6).⁹ Only 1 of the studies (12 patients) was rated as low-risk of bias. Risk of bias was highest for the domains of patient selection, flow and timing, and reference standard. There were no applicability concerns. Of 2093 cases included in the analysis, there were 69 cases of T21, 13 cases of T18, and 3 cases of T13. Of the 69 cases of T21, there was 1 false-negative and 1 false-positive test (see Table 7). A limitation of this systematic review was the exclusion of 23% of cases, including a loss to follow-up of 483 patients and failure of the test in 70 patients. Evaluation of diagnostic accuracy for T13 was limited by the small number of cases.

Gil et al (2019) identified 8 studies published through March 2019 on the diagnostic performance of NIPS in twin pregnancies.¹⁰ All of the studies were considered to have a high-risk of bias in patient selection, and 7 of the 8 studies were rated as high-risk of bias in flow and timing. The index test and reference standard were rated as low-risk of bias. Many of the studies were conducted in Asia with tests that are not used in the U.S. Of 3807 cases reporting on detection of T21, there were 56 cases of T21 with 2 false-positives. Five studies (n=3161) reported on T18, with 18 positive cases and 1 false-positive test result. Three studies (n=2572) reported on the detection

of T13 in twin pregnancies; 1 case was correctly identified with 2 cases missed and 5 false-positive results.

Table 6. Characteristics Systematic Reviews for Fetal Aneuploidies

Study	No. of Studies	Study Populations	N (N Excluded)	Reference Standard of Studies	No. of Studies Rated as "High" or "Unclear" Risk of Bias		
					No Domains	1-2 Domains	>2 Domains
Liao et al (2017) ⁹	10	Women with twin pregnancy	2711 (618 excluded from analysis)	Fetal karyotyping or neonatal clinical examination	1	7	2
Gil et al (2019) ¹⁰	8	Women with twin pregnancy	3807	NR	0	8 with at least 1 domain at high or unclear risk of bias	

NR: not reported

Table 7. Systematic Review Results for Fetal Aneuploidies

	Trisomy Affected Pregnancies	Sensitivity (95% CI), %	Specificity (95% CI), %	FP	FN	Diagnostic Odds Ratio (95% CI)
Liao et al (2017) ⁹						
21	69	99 (92 to 100)	100 (99 to 100)	1	1	1298 (438 to 3844)
18	13	85 (55 to 98)	100 (99 to 100)			334 (35 to 3171)
13	3	100	100	0	0	
Gil et al (2019) ¹⁰						
21	56	98.2 (83.2 to 99.8)	100 (99.7 to 100)	2		
18	18	88.9 (64.8 to 97.2)	100 (99.8 to 100)	1		
13	3	66.7 (NR)	99.8 (NR)	5/2569		

Adapted from Liao et al (2017).⁹

CI: confidence interval; FN: false-negative; FP: false-positive; NR: not reported.

Observational Studies

Four observational studies published after the systematic reviews conducted by Liao et al (2017) and Gil et al (2019) (Table 8).^{11,12} Notable limitations of these studies are shown in Tables 9 and 10.

Table 8. Observational Studies of NIPS in Twin or Multiple Pregnancies- Study Results

Study	Initial N	Final N	Excluded Samples	Prevalence of Condition	Clinical Validity	
					Sensitivity	Specificity
Dyr et al (2019) ¹¹	30,826	28,992	1,834 (5.95%) non-reportable (low fetal fraction)	(Confirmed cases) T21:16; T18: 8; T13:3	T21: 98.4%; T18: 99.99%; T13: 99.99%	T21: 99.9%; T18: >99.99%; T13: 99.28%
Kypri et al (2019) ¹²	306 twin pregnancies	300	6 with insufficient fetal fraction	T21: 3; T18: 1; T13: 1	100%	100%
Motevasselian et al (2020) ¹³	500 twin pregnancies	356	144 excluded: 94 did not come for follow-up, 22 no karyotype; 7 intrauterine death of both fetuses; 2 twin pregnancies had selective embryonic reduction, 19 terminated due to preterm labor (n = 11), premature rupture of membranes (n = 7) and severe preeclampsia (n = 1).	T21: 3; T18: 1; T13: 1	100%	99.7% (1 false positive)

Study	Initial N	Final N	Excluded Samples	Prevalence of Condition	Clinical Validity
Norwitz et al (2019) ²	126 twin pregnancies	117	10 confirmed euploid samples did not receive a cfDNA result. Of 87 euploid samples with gestational age \geq 10 weeks, 0/21 MZ and 10/66 DZ samples did not receive a result: Overall no-result rate 10.6% (95% CI 5.3% - 19.7%)	11 aneuploid; 106 euploid T21: 5 (1 MZ, 4 DZ); T18: 5 (all DZ); T13: 1 (DZ)	DZ Overall aneuploidy (96/96):100% (95% CI 94.8%-100%) gestations: 100% (95% CI 69.2% - 100%)

cfDNA: cell-free DNA; CI: confidence interval; DZ: dizygotic; MZ: monozygotic; N: sample size; T: trisomy.

Table 9. Observational Studies of NIPS in Twin or Multiple Pregnancies- Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Dyr et al (2019) ¹¹	4. Indications for NIPT varied				
Kypri et al (2019) ¹²					
Motevasselian et al (2020) ¹³	4. Indications for NIPT varied				
Norwitz et al (2019) ²					

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

^c Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

^d Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

^e Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).

Table 10. Observational Studies of NIPS in Twin or Multiple Pregnancies- Study Design and Conduct Limitations

Study	Selection ^a	Blinding ^b	Delivery of Test ^c	Selective Reporting ^d	Data Completeness ^e	Statistical ^f
Dyr et al (2019) ¹¹	2. Convenience sample				3. Outcome data on confirmed results reported voluntarily	1. Confidence intervals not reported
Kypri et al (2019) ¹²						1. Confidence intervals not reported
Motevasselian et al (2020) ¹³					2. 28% of pregnancies excluded	1. Confidence intervals not reported
Norwitz et al (2019) ²	1. Unclear if random or consecutive samples					

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

^b Blinding key: 1. Not blinded to results of reference or other comparator tests.

^c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

^d Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

^f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

Section Summary: Clinically Valid

Meta-analyses have identified 10 studies assessing the clinical validity of NIPS for detecting aneuploidies in twin pregnancies. Four additional observational studies have been published after these systematic reviews. The total number of cases of trisomies identified in meta-analyses was less than 100 and there were even fewer cases of T18 and T13. Additional observational studies added 48 more cases of trisomies (including 27 occurrences of T21) and reported high sensitivity and specificity of NIPS to identify trisomies compared to standard methods. However, these estimates were imprecise, with wide confidence intervals. The quantity and quality of evidence remains insufficient to draw conclusions about clinical validity.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Review of Evidence

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Direct evidence is not available for the evaluation of noninvasive prenatal testing to detect fetal aneuploidies in women pregnant with twins or multiples.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

It is not possible to construct a chain of evidence for clinical utility due to the lack of sufficient evidence on clinical validity.

Section Summary: Clinically Useful

There is a lack of direct evidence of clinical utility, and a chain of evidence cannot be constructed due to insufficient evidence on clinical validity.

Noninvasive Screening for Fetal Microdeletions Using Cell-Free Fetal DNA

Clinical Context and Test Purpose

The purpose of NIPS using analysis of cell-free fetal DNA in patients who are pregnant is to inform a decision whether to proceed with diagnostic testing.

The questions addressed in this evidence review are as follows: In pregnant individuals, does NIPS for fetal microdeletions have better diagnostic accuracy than standard approaches and does NIPS lead to improvements in health outcomes?

The following PICO was used to select literature to inform this review.

Patients

The relevant population of interest are women who are pregnant.

Interventions

The intervention of interest is NIPS using analysis of cell-free fetal DNA.

The test would be used in the primary care or specialty care setting (i.e., obstetrics-gynecology). Genetic counseling may also be necessary.

The timing for testing is generally in the first trimester of pregnancy and can be early in the second trimester.

Comparators

The following tests are currently being used to make decisions about identifying fetal microdeletions: Current practice is to offer invasive prenatal diagnostic testing in select cases to women when a prenatal ultrasound indicates anomalies (e.g., heart defects, cleft palate) that could be associated with a particular microdeletion syndrome.

Outcomes

The primary outcomes of interest are test accuracy and validity, reductions in miscarriages associated with invasive confirmatory testing, and reduction in the use of other noninvasive and invasive tests received by the pregnant individuals.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

Several studies have reported on the clinical validity of NIPS for detecting microdeletion syndromes (see Table 11). Gross et al (2016) and Helgeson et al (2015) reported on positive NIPS results for high-risk women.^{14,15} Petersen et al (2017) compared test results from amniotic or chorionic samples of unselected women referred for diagnostic testing due to a positive NIPS result. The positive predictive value (PPV) of NIPS to identify a microdeletion syndrome ranged from 13% in Petersen et al (2017) and 18% in Gross et al (2017) to 77% in Helgeson et al (2015). The basis for the large variance in the PPV is unclear, although Helgeson et al (2015) reported that, in 25 of the 55 microdeletions identified by NIPS, a maternal component was identified. In at least 5 cases, deletions were confirmed in the pregnant woman but not in the fetus. Gross et al (2017) reported that 8 (73%) of the 11 true-positive cases in their study could have been identified without NIPS (i.e., by ultrasound followed by invasive testing). A limitation of all studies is the lack of reporting on false-negatives because follow-up after negative screening results was voluntary and/or not available from the retrospective review of de-identified data.

Table 11. Systematic Review Characteristics for Microdeletions

Study	Test	Syndrome	Population	Reference Test	Comment
Gross et al (2016) ¹⁴	Natera	22q11.2	DiGeorge	20,776 samples from high-risk pregnant women submitted for screening	Diagnostic testing in 61
Petersen et al (2017) ¹⁶	Various	<ul style="list-style-type: none"> • 1p36 • 5p- • 15q- • 22q11.2 	<ul style="list-style-type: none"> • 1p36 • Cri du chat • Prader-Willi • DiGeorge 	52 cases referred for diagnostic testing following positive NIPS for MDS	Diagnostic CMA, FISH, or karyotyping
Helgeson et al (2015) ¹⁵	Sequenom MPS-based test	<ul style="list-style-type: none"> • 1p36 • 5p- • 15q- • 22q11.2 	<ul style="list-style-type: none"> • 1p36 • Cri du chat • Prader-Willi • DiGeorge 	175,393 samples from high-risk pregnant women submitted for screening	Diagnostic CMA, FISH, or clinical suspicion In at least 5 cases, deletions were confirmed in the pregnant woman but not in the fetus

CMA: chromosomal microarray; FISH: fluorescence in-situ hybridization; MDS: microdeletion syndromes; MPS: massively sequencing; NIPS: noninvasive prenatal screening.

Table 12. Systematic Review Results for Microdeletion Syndromes

Study	Initial N	Final N	Excluded Samples	Positive Tests, n (%)	Clinical Validity			
					TP, n (%)	PPV, %	FP	FN
Gross et al (2016) ¹⁴	21,949	20,776	1172	97 (0.46)	11 (0.05)	18	86	Unknown
Petersen et al (2017) ¹⁶	52	52	NR	52	7	13	45	Unknown
Helgeson et al (2015) ¹⁵	175,393		NR	55 (0.03)	41	77.4% ^a	3	Unknown

FN: false-negatives; FP: false-positives; NR: not reported; PPV: positive predictive value; TP: true-positives.

^a An additional 9 cases did not have confirmatory testing but had clinical features consistent with 1 of the microdeletions.

Section Summary: Clinically Valid

Several studies on the clinical validity of microdeletion testing have been published; they are based on large numbers of samples submitted to the testing companies. The PPV in these studies ranged from 18% to 77%. Another study evaluated diagnostic test results for women who had received a positive NIPS result, finding a PPV of only 13%. These studies have limitations (e.g., missing data on confirmatory testing, lack of complete data on false-negatives). Many (up to 73%) of the cases of microdeletion syndromes may also be detected by characteristic anomalies seen on prenatal ultrasound.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Review of Evidence

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are no direct data on whether sequencing-based testing for microdeletions improves outcomes compared with standard care.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The clinical utility of testing for any particular microdeletion or any panel of microdeletions is uncertain.

There is a potential that prenatal identification of individuals with microdeletion syndromes could improve health outcomes due to the ability to allow for informed reproductive decision making and/or initiate earlier treatment; however, data demonstrating improvement are unavailable. Given the variability of expressivity of microdeletion syndromes and the lack of experience with routine genetic screening for microdeletions, clinical decision making based on genetic test results is not well defined. It is not clear what follow-up testing or treatments might be indicated for screen-detected individuals.

Most treatment decisions would be made after birth, and it is unclear whether testing in utero would lead to earlier detection and treatment of clinical disease after birth. Moreover, clinical decision making when a maternal microdeletion is detected in pregnant women without previous knowledge of a genetic variant is unclear.

Section Summary: Clinically Useful

Maternal plasma DNA sequencing-based tests for fetal microdeletions have been proposed for use in a similar setting as noninvasive screening for fetal aneuploidies. However, there is currently no widely accepted clinical use for screening for microdeletions and microduplications in early pregnancy. Other potential uses are for diagnosis of suspected genetic disorders.

The clinical utility of NIPS for microdeletions is not well-established. Although there is potential for clinical utility in screening for some syndromes associated with microdeletions early in pregnancy, the clinical management changes that would be associated with early diagnosis of these syndromes are not well-established, and the potential for outcome improvements associated with early diagnosis (i.e., before the diagnosis would be suspected on the basis of physical exam findings or findings on routine imaging) is not well-established. The incidence of microdeletions syndromes is low, and not all individuals with a microdeletion will have clinical symptoms.

Noninvasive Prenatal Testing with Cell-Free DNA for Zygosity in Twin Pregnancies

Clinical Context and Test Purpose

The purpose of noninvasive prenatal testing (NIPT) using analysis of cell-free fetal DNA (cfDNA) in individuals who have a twin pregnancy is to inform decisions about early surveillance for twin-to-twin transfusion syndrome (TTTS) and other monochorionic (MC) twin-related abnormalities.

The question addressed in this evidence review is: In individuals who have a twin pregnancy, does NIPT for twin zygosity lead to improvements in health outcomes?

The following PICO was used to select literature to inform this review.

Patients

The relevant population of interest is individuals with twin pregnancies.

Twin gestations occur in approximately 1 in 30 live births in the United States and have a 4- to 10-fold increased risk of perinatal complications. Monochorionic (MC) twins account for about 20% of twin gestations and are at higher risk of structural defects, miscarriage, preterm delivery, and selective fetal growth restriction compared to dichorionic (DC) twins. Up to 15% of MC twin pregnancies are affected by twin to twin transfusion syndrome (TTTS), a condition characterized by relative hypovolemia of 1 twin and hypervolemia of the other. In these twin pregnancies, serial fetal ultrasound examinations are necessary to monitor for development of TTTS as well as selective intrauterine growth restriction because these disorders have high morbidity and mortality and are amenable to interventions that can improve outcomes.

Interventions

The intervention of interest is NIPT to determine zygosity using analysis of cell-free fetal DNA.

NIPT to determine zygosity in twin pregnancies could potentially inform decisions about early surveillance for TTTS and other monochorionic twin-related abnormalities.

The timing for testing is generally in the first trimester of pregnancy and can be early in the second trimester.

The test would be used in the primary care or specialty care setting (i.e., obstetrics-gynecology). Genetic counseling may also be necessary.

Comparators

Ultrasound examination performed in the first trimester or early second trimester is used to distinguish between MC and DC twins.

Outcomes

The primary outcomes of interest are test accuracy and validity, reduction in the use of other noninvasive and invasive tests received by the pregnant individuals, and reduction in morbidity and mortality associated with twin-to-twin transfusion syndrome and other monochorionic twin-related abnormalities.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

Observational Study

Norwitz et al (2019) conducted a validation study of a single-nucleotide polymorphism-based NIPT in twin pregnancies (Table 13). Twin zygosity results from this study are shown in Table 14. Of 126 total twin pregnancies, 95 samples with confirmed zygosity were available. Two of the 95 samples did not receive results due to low fetal fraction. Among the 93 pregnancies that yielded results, monozygotic sensitivity was 100% (29/29) and monozygotic specificity was 100% (64/64).

Study limitations are summarized in Tables 15 and 16. A major limitation was a lack of information on timing of the index test and the use of different methods to confirm zygosity.

Table 13. Validation Study of Cell-Free Fetal DNA Testing for Twin Zygosity- Study Characteristics

Study	Study Population	Design	Reference Standard	Timing of Reference and Index Tests	Blinding of Assessors
Norwitz et al (2019)	95 twin pregnancies	Prospective, unclear if random or consecutive	Confirmed zygosity, MZ or DZ determined by molecular genetic testing by an external laboratory (n = 47), presence of twins with different fetal sex (n = 36, only valid for DZ), SNP-based analysis of buccal samples from children (n = 8), clinical presentation of twin-to-twin transfusion syndrome (n = 3), or single embryo transfer plus monochorionic/monoamniotic observation by ultrasound (n = 1).	Timing of reference test not described	Yes

DZ: dizygotic; MA: monozygotic.

Table 14. Validation Study of Cell-Free Fetal DNA Testing for Twin Zygosity- Results

Study	Initial N	Final N	Excluded Samples	Prevalence of Condition	Clinical Validity	
					MZ Sensitivity/DZ Specificity	MZ Specificity/DZ Sensitivity
Norwitz et al (2019)	95	93	Overall 2.1% (no result due to low fetal fraction) MZ: 1/30 (3.3%) DZ: 1/65 (1.5%)	29 MZ, 64 DZ	100% (29/30) (95% CI 88.1%-100%)	100% (64/65) (95% CI 94.4%-100%)

CI: confidence interval; DZ: dizygotic; MA: monozygotic; N: sample size.

Table 15. Validation Study of Cell-Free Fetal DNA Testing for Twin Zygosity- Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Norwitz et al (2019)			3. Techniques to confirm zygosity varied		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

^c Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

^d Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

^e Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).

Table 16. Validation Study of Cell-Free Fetal DNA Testing for Twin Zygosity- Study Design and Conduct Limitations

Study	Selection ^a	Blinding ^b	Delivery of Test ^c	Selective Reporting ^d	Data Completeness ^e	Statistical ^f
Norwitz et al (2019)	1. Unclear if random or consecutive samples		1,2. Unclear when index testing occurred			

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

^b Blinding key: 1. Not blinded to results of reference or other comparator tests.

^c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

^d Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

^f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

Section Summary: Clinically Valid

One validation study conducted in 95 twin pregnancies found 100% sensitivity (95% CI 88.1% to 100%) and 100% specificity (95% CI 94.4% to 100%) for determining zygosity. These results need to be confirmed in additional, well-conducted studies to draw conclusions about clinical validity.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Review of Evidence

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are no direct data on whether cell-free fetal DNA testing for twin zygosity improves outcomes compared with standard care.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Section Summary: Clinically Useful

There are no studies of the clinical utility of NIPT using cell-free fetal DNA to determine zygosity, and the evidence on clinical validity is limited to 1 validation study of fewer than 100 twin pregnancies.

Noninvasive Prenatal Screening Using Vanadis NIPT for Chromosomal Trisomies in Singleton Pregnancies

Clinical Context and Test Purpose

The purpose of Vanadis NIPT using cell-free fetal DNA is to screen for fetal chromosomal abnormalities (e.g., trisomies 21, 18, 13 [T21, T18, T13]). It can be used as a complement or alternative to conventional serum screening. National guidelines have recommended that all pregnant women be offered screening for aneuploidies. Positive cell-free fetal DNA tests need to be confirmed using invasive testing and, if more accurate than standard screening may reduce the need for invasive testing and associated morbidities.

The purpose of Vanadis NIPT using analysis of cell-free fetal DNA in patients who have singleton pregnancy is to inform a decision whether to proceed with diagnostic testing.

The question addressed in this evidence review is as follows: In pregnant individuals, does Vanadis NIPT for chromosomal aneuploidies lead to improvements in health outcomes?

The following PICO was used to select literature to inform this review.

Patients

The relevant population of interest are women with first- and second-trimester singleton pregnancy.

Interventions

The intervention of interest is Vanadis NIPT using analysis of cell-free fetal DNA for detection of chromosomal trisomies 21, 18, and 13.

Comparators

The following tests are currently being used to make decisions about identifying fetal chromosomal abnormalities: conventional serum and ultrasound screening followed by invasive diagnostic testing as well as standard of care without screening.

Outcomes

The primary outcomes of interest are test accuracy and validity, reductions in miscarriages associated with invasive confirmatory testing, and reduction in the use of other noninvasive and invasive tests received by the pregnant individuals. The timing for testing is generally in the first trimester of pregnancy and can be early in the second trimester.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

In a proof of concept study, Vanadis NIPT analyzed chromosome 21¹⁷. For the case-control study 2 sample sets were collected; confirmed trisomy 21 pregnancies samples were collected from pregnant women carrying 1 affected fetus, with samples collected in association with termination, and as controls women with euploid singleton pregnancies were collected in association with first trimester screening after gestational week 9. In total 17 samples from pregnancies affected with trisomy 21 were collected and 165 samples from normal pregnancies. Using an age adjusted risk cut-off higher than 1%, all affected and normal samples were classified correctly. Additionally, a prospective high risk sample cohort consisted of plasma samples collected prospectively before invasive testing from singleton pregnancies at week 11-22 classified as high risk for trisomy 21. In total there were 13 positive trisomy 21 pregnancies which all were classified correctly using an age adjusted risk cut-off of 1%. No false positives were recorded. Additional and larger studies are required to demonstrate the application and performance of the Vanadis NIPT assay in a prospectively collected population cohort for screening trisomy 21 and additional chromosomes.

In 2019 the clinical performance of Vanadis NIPT was reported¹⁸. Maternal plasma samples from 1200 singleton pregnancies from prospectively and retrospectively collected high-risk cohorts were analyzed by Vanadis NIPT with reference outcomes determined by either cytogenetic testing, of amniotic fluid or chorionic villi, or clinical examination of neonates. Of these samples, 158 fetal aneuploidies were identified. Sensitivity was 100% (112/112) for trisomy 21 (95% CI, 96.8%-100%), 89% (32/36) for trisomy 18 (95% CI, 73.9%-96.9%), and 100% (10/10) for trisomy 13 (95% CI, 69.2%-100%); with respective specificities of 100% (95% CI, 99.6%-100%), 99.5% (95% CI, 98.9%-99.8%), and 99.9% (95% CI, 99.5%-100%). There were 5 first pass failures (0.4%), all in

unaffected pregnancies. Sex classification was performed on 979 of the samples and 99.6% (975/979) provided a concordant result.

Section Summary: Clinically Valid

One proof of concept study and 1 clinical validation study of Vanadis NIPT have been published. Among 1200 singleton pregnancies, Vanadis NIPT had a sensitivity of 100% (95% CI, 96.8%-100%) and specificity of 100% (95% CI, 99.6%-100%) for trisomy 21; the respective values for trisomy 18 were 89% (95% CI, 73.9%-96.9%) and 99.5% (95% CI, 98.9%-99.8%), and for trisomy 13 were 100% (95% CI, 69.2%-100%) and 99.9% (95% CI, 99.5%-100%). These results need to be confirmed in additional, well-conducted studies to draw conclusions about clinical validity.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Review of Evidence

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are no direct data on whether cell-free fetal DNA testing with Vanadis NIPT for singleton pregnancy improves outcomes compared with standard care.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Section Summary: Clinically Useful

There are no studies of the clinical utility of Vanadis NIPT using cell-free fetal DNA to determine aneuploidy in singleton pregnancy, and the current evidence is limited to 1 proof of concept study and 1 clinical validation study.

Summary of Evidence

For individuals who have a singleton pregnancy who receive NIPS for T21, T18, and T13 using cell-free fetal DNA, the evidence includes observational studies and systematic reviews. Relevant outcomes are test accuracy and validity, morbid events, and resource utilization. Published studies on available tests and meta-analyses of these studies have consistently demonstrated very high sensitivity and specificity for detecting Down syndrome (T21) in singleton pregnancies. Most studies included only women at high-risk of T21 but several studies have reported similar levels of diagnostic accuracy in average-risk women. Compared with standard serum screening, both the sensitivity and specificity of cell-free fetal DNA screening are considerably higher. As a result, screening with cell-free fetal DNA for T21 will result in fewer missed cases of Down syndrome, fewer invasive procedures, and fewer cases of pregnancy loss following invasive procedures. Screening for T18 and T13 along with T21 may allow for preparation for fetal demise or termination of the pregnancy prior to fetal loss. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a singleton pregnancy who receive NIPS for sex chromosome aneuploidies using cell-free fetal DNA, the evidence includes observational studies, mainly in high-risk pregnancies, and systematic reviews. Relevant outcomes are test accuracy and validity, morbid events, and resource utilization. Meta-analyses of available data have suggested high sensitivities and specificities but the small number of cases makes definitive conclusions difficult. In addition, the clinical utility of identifying sex chromosome aneuploidies

during pregnancy is uncertain. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a twin or multiple pregnancy who receive NIPS for aneuploidies using cell-free fetal DNA, the evidence includes observational studies and systematic reviews. Relevant outcomes are test accuracy and validity, morbid events, and resource utilization. The total number of cases of aneuploidy identified in these studies is small and is insufficient to draw conclusions about clinical validity. There is a lack of direct evidence of clinical utility, and a chain of evidence cannot be conducted due to the paucity of evidence on clinical validity. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with pregnancy(ies) who receive NIPS for microdeletions using cell-free fetal DNA, the evidence includes several observational studies. Relevant outcomes are test accuracy and validity, morbid events, and resource utilization. The available studies on clinical validity have limitations (e.g., missing data on confirmatory testing, false-negatives), and the added benefit of NIPS compared with current approaches is unclear. Moreover, the clinical utility of NIPS for microdeletions remains unclear and has not been evaluated in published studies. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have twin pregnancy who receive noninvasive prenatal testing (NIPT) for twin zygosity using cell-free fetal DNA, the evidence includes an observational study. Relevant outcomes are test accuracy and validity, morbid events, and resource utilization. Sensitivity and specificity were high (100%) in 1 validation study conducted in 95 twin gestations. This evidence is too limited to draw conclusions about performance characteristics and would need to be confirmed in additional, well-conducted studies. Moreover, the clinical utility of NIPT for twin zygosity compared to standard methods such as ultrasound is unclear and has not been evaluated in published studies. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a singleton pregnancy who receive NIPS for T21, T18, and T13 using Vanadis NIPT, the evidence includes 2 industry sponsored studies. Relevant outcomes are test accuracy and validity, morbid events, and resource utilization. The available studies on clinical validity have limitations, and the added benefit of Vanadis NIPT compared with current approaches is unclear. Moreover, the clinical utility of Vanadis NIPT remains unclear and has not been evaluated in published studies. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests from Blue Cross Blue Shield Association, input was received from 3 physician specialty societies and 4 academic medical centers in 2013. There was a consensus that sequencing-based tests to determine trisomy 21 (T21) from maternal plasma cell-free fetal DNA may be considered medically necessary in women with high-risk singleton pregnancies undergoing screening for T21. The input was mixed on whether sequencing-based tests to determine T21 from maternal plasma DNA may be considered medically necessary in women with average-risk singleton pregnancies. An American College of Obstetricians and Gynecologists genetics committee opinion, included as part of the specialty society's input, did not then recommend the new tests for women with singleton pregnancies who were not at high-risk of aneuploidy. There was a consensus that sequencing-based tests to determine T21 from maternal plasma DNA are investigational for women with multiple pregnancies. Regarding an appropriate protocol for using sequencing-based testing, there was a consensus that testing

should not be used as a single screening test without confirmation of results by karyotyping. There was mixed input on the use of the test as a replacement for standard screening tests with karyotyping confirmation and on use as a secondary screen in women with screen positive on standard screening tests with karyotyping confirmation. Among the 5 reviewers who responded to the questions (which did not include the American College of Obstetricians and Gynecologist), there was a consensus that the modeling approach is sufficient to determine the clinical utility of the new tests and near-consensus there is no need for clinical trials comparing a screening protocol using the new tests to a screening protocol using standard serum screening before initiation of clinical use of the tests.

Practice Guidelines and Position Statements

American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine

In 2016, the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine released a joint practice bulletin summary (No. 163) on the screening for fetal aneuploidy.¹⁹ The following recommendations on cell-free DNA were based on "good and consistent" scientific evidence:

- "Women who have a negative screening test result should not be offered additional screening tests for aneuploidy because this will increase their potential for a false-positive test result."
- "Because cell-free DNA is a screening test with the potential for false-positive and false-negative results, such testing should not be used as a substitute for diagnostic testing."
- "All women with a positive cell-free DNA test result should have a diagnostic procedure before any irreversible action, such as pregnancy termination, is taken."
- "Women whose cell-free DNA screening test results are not reported, are indeterminate, or are uninterpretable (a no-call test result) should receive further genetic counseling and be offered comprehensive ultrasound evaluation and diagnostic testing because of an increased risk of aneuploidy."

The following recommendations were based on "limited or inconsistent" scientific evidence:

- "Cell-free DNA screening tests for microdeletions have not been validated clinically and are not recommended at this time."
- "No method of aneuploidy screening is as accurate in twin gestations as it is in singleton pregnancies. Because data generally are unavailable for higher-order multifetal gestations, analyte screening for fetal aneuploidy should be limited to singleton and twin pregnancies."

The following recommendations are based "primarily on consensus and expert opinion":

- "Some women who receive a positive test result from traditional screening may prefer to have cell-free DNA screening rather than undergo definitive testing."
- "This approach may delay definitive diagnosis and management and may fail to identify some fetuses with aneuploidy."
- "Parallel or simultaneous testing with multiple screening methodologies for aneuploidy is not cost-effective and should not be performed."

American College of Medical Genetics and Genomics

In 2016, the American College of Medical Genetics and Genomics published a position statement on noninvasive prenatal screening (NIPS) for fetal aneuploidy.²⁰ The relevant recommendations are as follows:

- "Informing all pregnant women that NIPS is the most sensitive screening option for traditionally screened aneuploidies (i.e., Patau, Edwards, and Down syndromes)."
- "Referring patients to a trained genetics professional when an increased risk of aneuploidy is reported after NIPS."
- "Offering diagnostic testing when a positive screening test result is reported after NIPS."
- "Providing accurate, balanced, up-to-date information, at an appropriate literacy level when a fetus is diagnosed with a chromosomal or genomic variation in an effort to

educate prospective parents about the condition of concern. These materials should reflect the medical and psychosocial implications of the diagnosis."

The American College of Medical Genetics and Genomics did not recommend "NIPS to screen for autosomal aneuploidies other than those involving chromosomes 13, 18, and 21."

International Society for Prenatal Diagnosis

In 2015, the International Society for Prenatal Diagnosis published a position statement on the prenatal diagnosis of chromosomal abnormalities, updating its 2013 statement.^{21,22} (Note that a number of the authors of the 2015 report had financial links to industry.) The following summarizes the Society's recommendations:

- I. High sensitivities and specificities are potentially achievable with cfDNA [cell-free DNA] screening for some fetal aneuploidies, notably trisomy 21.
- II. Definitive diagnosis of Down syndrome and other fetal chromosome abnormalities can only be achieved through testing on cells obtained by amniocentesis or CVS [chorionic villous sampling].
- III. The use of maternal age alone to assess fetal Down syndrome risk in pregnant women is not recommended.
- IV. A combination of ultrasound NT [nuchal translucency] measurement and maternal serum markers in the first trimester should be available to women who want an early risk assessment and for whom cfDNA screening cannot be provided.
- V. A 4 marker serum test should be available to women who first attend for their prenatal care after 13 weeks 6 days of pregnancy and where cfDNA screening cannot be provided.
- VI. Protocols that combine first trimester and second trimester conventional markers are valid.
- VII. Second trimester ultrasound can be a useful adjunct to conventional aneuploidy screening protocols.
- VIII. When cfDNA screening is extended to microdeletion and microduplication syndromes or rare trisomies the testing should be limited to clinically significant disorders or well defined severe conditions. There should be defined estimates for the detection rates, false-positive rates, and information about the clinical significance of a positive test for each disorder being screened."

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force does not currently address screening for Down syndrome. This syndrome was addressed in the 1990s; it is no longer listed on the Task Force website.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this evidence review are listed in Table 17.

Table 17. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT03375359	First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome - ReFaPo02	1000	Dec 2020
NCT01545674 ^a	Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)	1000	Dec 2020
NCT02381457 ^a	SNP-based Microdeletion and Aneuploidy RegisTry (SMART)	20960	Mar 2020
NCT04437992 ^a	Feasibility Study of a New Screening Program for Major Aneuploidies (T21, T18, T13) in the Emilia-Romagna Region (SAPERER)	7000	Apr 2021

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT03559374 ^a	Study of Vanadis NIPT for Non-Invasive prenatal Screening of Trisomies (T21, T18, and T13)	1200	Aug 2020
Unpublished			
NCT03200041 ^a	Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies	1000	Jul 2019
NCT01472523 ^a	A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood	1632	Jul 2019

NCT: national clinical trial.

^aDenotes industry-sponsored or cosponsored trial.

References

1. Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. *JAMA*. Apr 15 1983; 249(15): 2034-8. PMID 6220164
2. Norwitz ER, McNeill G, Kalyan A, et al. Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy. *J Clin Med*. Jun 28 2019; 8(7). PMID 31261782
3. UptoDate (2020). Twin-twin transfusion syndrome and twin anemia polycythemia sequence: Screening, prevalence, pathophysiology, and diagnosis. https://www.uptodate.com/contents/twin-twin-transfusion-syndrome-and-twin-anemia-polycythemia-sequence-screening-prevalence-pathophysiology-and-diagnosis?search=twin%20twin%20transfusion%20syndrome&source=search_result&selectedTitle=1~35&usage_type=default&display_rank=1. Accessed July 29, 2020.
4. Chitty LS, Hudgins L, Norton ME. Current controversies in prenatal diagnosis 2: Cell-free DNA prenatal screening should be used to identify all chromosome abnormalities. *Prenat Diagn*. Feb 2018; 38(3): 160-165. PMID 29417608
5. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Noninvasive prenatal cell-free fetal DNA-based screening for aneuploidies other than trisomy 21. TEC Assessment Program. 2014; Volume 29: Tab 7.
6. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Sequencing-based tests to determine fetal down syndrome (trisomy 21) from maternal plasma DNA. TEC Assessment Program. 2013; Volume 27: Tab 10.
7. Badeau M, Lindsay C, Blais J, et al. Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. *Cochrane Database Syst Rev*. Nov 10 2017; 11: CD011767. PMID 29125628
8. Ohno M, Caughey A. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis. *Prenat Diagn*. Jul 2013; 33(7): 630-5. PMID 23674316
9. Liao H, Liu S, Wang H. Performance of non-invasive prenatal screening for fetal aneuploidy in twin pregnancies: a meta-analysis. *Prenat Diagn*. Sep 2017; 37(9): 874-882. PMID 28728213
10. Gil MM, Galeva S, Jani J, et al. Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis. *Ultrasound Obstet Gynecol*. Jun 2019; 53(6): 734-742. PMID 31165549
11. Dyr B, Boomer T, Almasri EA, et al. A new era in aneuploidy screening: cfDNA testing in 30,000 multifetal gestations: Experience at one clinical laboratory. *PLoS ONE*. 2019; 14(8): e0220979. PMID 31393959
12. Kypri E, Ioannides M, Touvana E, et al. Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test. *Mol Cytogenet*. 2019; 12: 34. PMID 31338126
13. Motevasselian M, Saleh Gargari S, Younesi S, et al. Non-invasive prenatal test to screen common trisomies in twin pregnancies. *Mol Cytogenet*. 2020; 13: 5. PMID 32042312
14. Gross SJ, Stosic M, McDonald-McGinn DM, et al. Clinical experience with single-nucleotide polymorphism-based non-invasive prenatal screening for 22q11.2 deletion syndrome. *Ultrasound Obstet Gynecol*. Feb 2016; 47(2): 177-83. PMID 26396068

15. Helgeson J, Wardrop J, Boomer T, et al. Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing. *Prenat Diagn.* Oct 2015; 35(10): 999-1004. PMID 26088833
16. Petersen AK, Cheung SW, Smith JL, et al. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory. *Am J Obstet Gynecol.* Dec 2017; 217(6): 691.e1-691.e6. PMID 29032050
17. Dahl F, Ericsson O, Karlberg O, et al. Imaging single DNA molecules for high precision NIPT. *Sci Rep.* 2018;8(1):4549. Published 2018 Mar 14. doi:10.1038/s41598-018-22606-0
18. Ericsson O, Ahola T, Dahl F, et al. Clinical validation of a novel automated cell-free DNA screening assay for trisomies 21, 13, and 18 in maternal plasma. *Prenat Diagn.* 2019;39(11):1011-1015. doi:10.1002/pd.5528
19. Practice Bulletin No. 163 Summary: Screening for Fetal Aneuploidy. *Obstet Gynecol.* May 2016; 127(5): 979-81. PMID 27101120
20. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med.* Oct 2016; 18(10): 1056-65. PMID 27467454
21. Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. *Prenat Diagn.* Aug 2015; 35(8): 725-34. PMID 25970088
22. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. *Prenat Diagn.* Jul 2013; 33(7): 622-9. PMID 23616385
23. Cell-free DNA to Screen for Single-Gene Disorder ACOG: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2019/02/cell-free-dna-to-screen-for-single-gene-disorders>
24. Cell-Free DNA: Screening for Single-Gene Disorders and Determination of Fetal Rhesus D Genotype: <https://pubmed.ncbi.nlm.nih.gov/29428284/>
25. Clinical experience of laboratory follow-up with noninvasive prenatal testing using cell-free DNA and positive microdeletion results in 349 cases S Schwartz¹, M Kohan², R Pasion¹, P R Papenhausen¹, L D Platt^{3,4} *Prenat Diagn.* 2018 Feb;38(3):210-218. doi: 10.1002/pd.5217. Epub 2018 Feb 26.
26. Blue Cross Blue Shield Association. Medical Policy Reference Manual, No. 4.01.21 (August 2020).

Documentation for Clinical Review

Please provide the following documentation:

- History and physical and/or consultation report including:
 - Documentation of choice to use NIPT instead of the CA prenatal screening program
 - Number of fetuses carried (e.g., single, twin, multiple)
 - Prior screening test result(s) for fetal aneuploidy or other genetic tests (of parents, fetus or siblings) and date performed
- Standard fetal aneuploidy testing results (e.g., first trimester screen, integrated screen, quad screen) (if done)
- Fetal ultrasound result(s) (if available)

Post Service (in addition to the above, please include the following):

- Lab reports specific to fetal aneuploidy or other genetic testing (e.g., initial aneuploidy testing, Nucleic acid sequencing-based testing of maternal plasma)

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms

of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

Type	Code	Description
CPT®	0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
	0168U	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy
	81420	Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
	81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood
	81479	Unlisted molecular pathology procedure
	81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
	81599	Unlisted multianalyte assay with algorithmic analysis
	84999	Unlisted chemistry procedure
	88271	Molecular cytogenetics; DNA probe, each (e.g., FISH)
HCPCS	None	

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
03/29/2013	BCBSA medical policy adoption
06/28/2013	Coding Update
01/09/2014	Coding Update
05/28/2014	Policy revision with position change
01/30/2015	Coding Update
05/29/2015	Coding Update
08/31/2015	Policy title change from Maternal Plasma Cell-free Fetal DNA Sequencing for Fetal Aneuploidy Detection Policy revision with position change
09/30/2015	Policy History clarification
03/01/2016	Policy Guidelines clarification
12/01/2016	Policy title change from Noninvasive Prenatal Screening for Fetal Aneuploidies Using Cell-Free Fetal DNA Policy revision without position change
10/01/2017	Policy revision without position change
07/01/2018	Policy statement clarification
11/01/2018	Policy revision without position change
08/01/2019	Policy revision without position change
10/01/2019	Policy revision without position change
11/01/2019	Coding update
03/01/2020	Coding update
07/01/2020	Coding update
08/01/2020	Coding update

Effective Date	Action
10/01/2020	Annual review. Policy statement and literature updated. Policy title changed from Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA to current one.
01/01/2021	Administrative update. Policy statement and guidelines updated.
04/01/2021	Annual review. Policy statement and guidelines updated.

Definitions of Decision Determinations

Medically Necessary: Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.

Appendix A

POLICY STATEMENT

BEFORE

Noninvasive Prenatal Screening for Fetal Aneuploidies, Microdeletions, and Twin Zygosity Using Cell-Free Fetal DNA 4.01.21**Policy Statement:**

Nucleic acid sequencing-based testing (Noninvasive Prenatal Testing or NIPT, also referred to as Noninvasive Prenatal Screening or NIPS) of a pregnant individual's plasma to screen for trisomy 21, 18, and 13 as an alternative to the California Prenatal Screening Program or similar (see Policy Guidelines section), may be considered **medically necessary** in women with singleton pregnancies.

Performing both the California Prenatal Screening Program (or similar) testing and NIPT during the same pregnancy is considered **not medically necessary**.

Nucleic acid sequencing-based testing of a pregnant individual's plasma is considered **investigational** in the following situations:

- I. For trisomy 21 in individuals with twin or multiple pregnancies
- II. For trisomy 13 and/or 18 other than in the situations specified above
- III. For microdeletions
- IV. For fetal sex chromosome aneuploidies
- V. For Vanadis NIPT to screen for trisomy 21, 18 and 13
- VI. For twin zygosity
- VII. For other aneuploidies not considered medically necessary as noted above, including but not limited to comprehensive screening of all 22 autosomes

AFTER

Blue font: Verbiage Changes/Additions**Noninvasive Prenatal Screening for Fetal Aneuploidies, Microdeletions, and Twin Zygosity Using Cell-Free Fetal DNA 4.01.21****Policy Statement:**

Nucleic acid sequencing-based testing (Noninvasive Prenatal Testing or NIPT, also referred to as Noninvasive Prenatal Screening or NIPS) of a pregnant individual's plasma to screen for trisomy 21, 18, and 13 as an alternative to the California Prenatal Screening Program or similar (see Policy Guidelines section), may be considered **medically necessary** in women with singleton pregnancies.

Performing both the California Prenatal Screening Program (or similar) testing and NIPT during the same pregnancy is considered **not medically necessary**.

Nucleic acid sequencing-based testing of a pregnant individual's plasma (i.e., **circulating cell free DNA**) is considered **investigational** in the following situations:

- I. For trisomy 21 in individuals with twin or multiple pregnancies
- II. For trisomy 13 and/or 18 other than in the situations specified above
- III. For microdeletions
- IV. For fetal sex chromosome aneuploidies
- V. **For single gene disorders, either individually or as a panel (e.g., Vistara)**
- VI. For Vanadis NIPT to screen for trisomy 21, 18 and 13
- VII. For twin zygosity
- VIII. For other aneuploidies **or genetic disorders** not considered medically necessary as noted above, including but not limited to comprehensive screening of all 22 autosomes